Mushrooms During Cancer Treatment: What Oncologists Say

Medicinal Mushrooms in Cancer Treatment

48 participants

In a double-blind RCT, reishi spore powder significantly reduced cancer-related fatigue and depression in breast cancer patients on endocrine therapy compared to placebo.

Gao Y et al., Evidence-Based Complementary and Alternative Medicine, 2012

Level 1

clinical evidence grade for PSK/turkey tail in gastric and colorectal cancer (Narayanan et al., 2023)

5 species

reviewed for integrative oncology applications by Tung et al., 2020

CYP450

liver enzyme pathway inhibited by reishi, affecting how many cancer drugs are metabolized

Gao Y et al., Evidence-Based Complementary and Alternative Medicine, 2012

View as image ↗

For cancer patients weighing mushroom supplements during cancer treatment, a 2023 systematic review of clinical evidence offers the clearest reference point yet. Narayanan and colleagues graded PSK, the active compound from turkey tail mushroom, at Level 1 clinical evidence for survival benefit in gastric and colorectal cancer when combined with chemotherapy.^[1] Level 1 is the highest evidence tier in clinical medicine. At the same time, the review identified meaningful drug interaction risks for several of the most widely used mushroom species in cancer patients. The evidence points in two directions at once: some mushroom compounds are better supported than most people realize, and some carry interaction risks that require clinical evaluation before use.

Every major systematic review of this evidence reaches the same structural conclusion: drug interactions with cancer medications can only be assessed when the treating oncologist knows what a patient is taking. The sections below cover what those interactions are, what the clinical trials show for quality of life and immune function, and how integrative oncologists navigate this evidence when working with patients. For the broader research picture covering mechanisms and the Japan prescription drug context, the complete guide to medicinal mushrooms in cancer treatment covers all of that in depth.

The Drug Interaction Map: Which Species Carry the Most Risk

The most critical safety question for anyone taking mushroom supplements during active cancer treatment is whether those supplements affect how the body processes cancer drugs. For reishi, the answer is yes, through a specific and measurable pathway.

Reishi (Ganoderma lucidum) contains compounds called triterpenoids that block a family of liver enzymes known as CYP450, specifically the 1A2, 2E1, and 3A4 pathways.^[2] The CYP450 system is how the body breaks down and eliminates many medications, including several widely used chemotherapy drugs and targeted therapies. When a key enzyme in that system is blocked, drugs that rely on it can accumulate to higher concentrations than intended, or clear from the body more slowly than the dosing protocol assumes. A drug calibrated to be therapeutic could, with CYP450 inhibition, reach concentrations closer to toxic.

Tung and colleagues identified this interaction as the primary pharmacological concern with reishi in cancer patients on active treatment in their 2020 review of medicinal mushrooms in integrative oncology.^[2] The interaction is theoretical at typical supplement doses, but the mechanism is established and clinically meaningful enough that it requires evaluation against each patient's specific drug protocol.

Turkey tail presents a different, lower-profile concern. PSK and PSP, the active polysaccharide compounds in turkey tail, may alter how the body processes tamoxifen and cyclophosphamide. Some data suggests this interaction could enhance tamoxifen's anti-tumor activity, but the pharmacological relationship means any patient on these drugs needs this information visible to their care team. Enhancement is still an interaction.

A species-level reference for the drug interaction landscape:

• Reishi: Inhibits CYP450 enzymes (1A2, 2E1, 3A4); highest established drug interaction risk among supplement-form mushrooms; most relevant for patients on chemotherapy or targeted therapies that rely on these pathways
• Turkey tail (PSK/PSP): May interact with tamoxifen and cyclophosphamide; requires disclosure; some evidence suggests possible enhancement of tamoxifen activity
• Shiitake (lentinan, IV form): 35-year prescription drug history in Japan for lung cancer; the IV pharmaceutical form has an established clinical record; oral shiitake supplements carry a lower established interaction risk
• Maitake: Limited clinical interaction data; NK cell activation studies exist but no established drug interaction profile from human trials
• Lion's mane, Chaga, Cordyceps: No established drug interaction data for cancer treatment contexts; insufficient clinical evidence to characterize the interaction risk

The absence of an established interaction profile for a species does not mean the interaction risk is zero. It means the interaction hasn't been studied well enough in cancer populations to characterize.

Turkey Tail Has the Strongest Evidence Grade in Oncology

When Narayanan and colleagues published their 2023 systematic review of clinical mushroom supplement studies, PSK received the highest evidence classification of any mushroom compound they evaluated.^[1]

Level 1 evidence means multiple randomized controlled trials pointing in the same direction, enough to inform clinical practice guidelines. For PSK in gastric and colorectal cancer, the evidence base includes a body of RCT data large enough that Narayanan classified it at the same tier used for pharmaceutical interventions. For context: the trial population across those studies runs into the tens of thousands. No other mushroom compound is close to that evidentiary level.

Lentinan, derived from shiitake (Lentinus edodes), received Level 2 evidence for lung cancer in the same review. Lentinan has been used as a prescription IV drug in Japan for over 35 years, which adds clinical framing: this is not a speculative supplement; it's a government-approved medication with a documented clinical history in lung cancer patients.^[1]

Reishi received a lower grade for direct anti-tumor effects but a meaningfully different picture for quality-of-life outcomes, particularly fatigue. The 2023 review is honest about this distinction: the QoL data for reishi is better controlled than its anti-tumor data, and the evidence grades reflect that difference.

What the Narayanan review also provides is a direct framework for what oncologists can say with confidence. For PSK in gastric and colorectal cancer, the evidence grade is sufficient for an integrative oncologist to support its use as an adjunct to standard chemotherapy, with monitoring and disclosure. For most other species, the evidence grade does not reach that threshold. For a structured walk-through of this evidence hierarchy, the research review on mushroom-based cancer adjuncts covers each tier in detail.

The Reishi Fatigue Trial: What a Double-Blind RCT Found

Most discussions of reishi and cancer patients stay vague about specific outcomes. One study changes that.

Gao and colleagues ran a double-blind, placebo-controlled RCT of reishi spore powder in 48 breast cancer patients undergoing endocrine therapy, the hormone treatment that follows primary cancer treatment.^[3] Breast cancer patients on endocrine therapy commonly experience significant fatigue, mood disruption, and reduced quality of life over the treatment period. The study found that reishi spore powder significantly reduced both cancer-related fatigue scores and depression measures compared to placebo over the trial period.

An earlier double-blind RCT by the same first author tested Ganoderma polysaccharide extract, a different reishi preparation, for fatigue and quality-of-life outcomes and found meaningful improvements over placebo there too.^[5] Across both trials, the target was the same: fatigue and subjective well-being, not tumor progression or recurrence.

What this evidence does not show: neither trial was designed to test whether reishi affects cancer outcomes, survival, or recurrence. The endpoint was quality of life during treatment, and that is what the trials measured. The Gao 2012 RCT is the strongest human evidence for reishi's cancer-related benefits, and the endpoint is fatigue reduction in breast cancer patients on endocrine therapy. That is a specific, valuable finding. It does not generalize to all cancer types, all treatment phases, or all reishi product forms.

The practical implication of the evidence is also limited by the CYP450 interaction concern described earlier. Reishi's fatigue benefit is real and controlled-trial-supported, but the interaction profile means it requires oncologist evaluation before use, particularly for patients on active chemotherapy rather than the endocrine therapy setting of the Gao trials.

Quality of Life Beyond Fatigue: What Turkey Tail Patients Report

The Gao trials give reishi the strongest controlled evidence for fatigue. Turkey tail's quality-of-life signal comes from a different angle.

Johnson and colleagues followed cancer patients in remission who were taking turkey tail (Coriolus versicolor) extract over the course of an observation period.^[4] Participants reported significant improvements in fatigue, sleep quality, pain levels, and emotional well-being scores over the study period. This was a cohort study rather than a placebo-controlled trial, which means it can show association but cannot isolate causation the way the Gao RCT can. The evidence is weaker on design. But the directional consistency across multiple QoL measures in cancer patients makes it a notable addition to the evidence base.

The immune mechanism connecting turkey tail to these outcomes has a measurable component in the natural killer cell data. Park and colleagues measured NK cell activity in cancer patients taking a mushroom extract and found improvements in NK cell function alongside quality-of-life gains.^[6] NK cells are the immune system's surveillance cells that identify and destroy abnormal or cancerous cells. Cancer treatment commonly suppresses NK cell activity. The mushroom extract data shows recovery or enhancement of that activity.

Taking the QoL evidence together: reishi has the stronger controlled-trial record for fatigue specifically, grounded in two RCTs. Turkey tail has broader QoL data across multiple measures in remission-phase patients. Both are consistent with the immune activation mechanisms identified in laboratory research, and both are subject to the standard limitations of supplement research, including variation in product quality and patient populations. For a deeper look at fatigue, sleep, and emotional well-being specifically, mushrooms and quality of life during cancer treatment covers this in greater depth.

What Integrative Oncologists Actually Recommend, and Where They Stop

Tung and colleagues, reviewing the integrative oncology evidence base for five major mushroom species in 2020, found that integrative oncologists take a species-specific, evidence-graded position with this research.^[2] They are not dismissing mushroom compounds as uniformly ineffective. They are also not broadly endorsing them across cancer types. They are applying evidence grades species by species, with attention to what is demonstrated in controlled human trials versus what is in cell-culture or animal studies.

The 2023 Narayanan systematic review sharpens this into a practical reference.^[1] For PSK in gastric and colorectal cancer, the evidence grade is sufficient for an integrative oncologist to support its use as an adjunct to standard chemotherapy with appropriate monitoring and disclosure. For lentinan (IV shiitake) in lung cancer, Level 2 evidence supports use, and the 35-year prescription history in Japan provides additional clinical grounding. For reishi as a QoL support in the specific context tested (breast cancer patients on endocrine therapy), the RCT evidence is credible enough for many oncologists to view it as appropriate with proper CYP450 interaction evaluation.

For lion's mane, chaga, cordyceps, and most of the species most heavily marketed in the supplement industry, integrative oncologists largely withhold a recommendation at this stage. The in vitro and animal data points in interesting directions. The clinical trials either do not exist or are too small and heterogeneous to draw conclusions from. Recommending a supplement to a cancer patient based on cell-culture data, when that patient is already navigating complex drug regimens, is a risk few evidence-minded clinicians will take.

One structural tension runs through all of this: the mushroom supplement industry cannot make cancer-related claims under US law, which means the most evidence-backed compounds are buried in the academic literature while less-evidenced species dominate supplement marketing. Why US mushroom supplements can't make cancer-related claims covers the regulatory context that shapes what products say and what they can't.

Forms and Timing: What the Clinical Trials Actually Studied

The clinical evidence for turkey tail and reishi comes from specific product forms. Whole mushroom powders and the forms used in clinical trials are not the same thing, and the distinction matters when evaluating whether a given product reflects what was tested.

PSK, used in the Japan-based trials and in the systematic reviews Narayanan analyzed, is a purified polysaccharide-K extract from Trametes versicolor mycelium. PSP (polysaccharide-P) is a related fraction used in some Chinese trials. Both are concentrated extracts, not whole mushroom powder. Whole-mushroom turkey tail products exist, but the clinical evidence base references the extracted fraction specifically.

Reishi evidence for cancer-related fatigue comes from spore powder, used in the Gao 2012 RCT, and from polysaccharide extract, used in the Gao 2005 RCT.^[3][5] The broad category of "reishi supplements" sold in the US includes everything from dual extracts to ground fruiting body powder, and none of those is identical to either trial preparation. The polysaccharide content may overlap, but the clinical evidence is tied to the specific forms tested.

The oncologist conversation is most productive when it includes: the specific product form (extract vs. powder, standardized vs. whole), the dose relative to trial doses (the reishi trials used standardized preparations; the PSK trials in Japan used 3g/day in many protocols), and any other supplements being taken for a complete interaction profile. The clinical trial data provides a reference point for what "studied" use looks like. Significant deviations in form or dose move further from the evidence base. For the evidence on managing specific chemotherapy side effects, mushrooms for chemotherapy side effects covers that research separately.

The Bottom Line

The clinical evidence for mushroom supplements during cancer treatment is species-specific and uneven. PSK from turkey tail has the strongest human evidence, carrying a Level 1 evidence grade for survival benefit in gastric and colorectal cancer when added to chemotherapy. Reishi has QoL RCT data for cancer-related fatigue, particularly in breast cancer patients on endocrine therapy, but also carries the most significant drug interaction risk through CYP450 enzyme inhibition. For most other mushroom species, clinical evidence in cancer patients is limited to preclinical data and small cohort studies. All major systematic reviews of this evidence conclude that full supplement disclosure to the treating oncologist is a prerequisite for safe use during active treatment.

Frequently Asked Questions

Is it safe to take mushroom supplements during chemotherapy?

Safety during chemotherapy depends heavily on the species and your specific drug protocol. Reishi inhibits CYP450 liver enzymes that metabolize many chemotherapy drugs, creating potential for drug accumulation at higher-than-intended concentrations. Turkey tail may interact with tamoxifen and cyclophosphamide. Shiitake-derived lentinan has a 35-year prescription history in Japan for lung cancer treatment and a lower established oral interaction risk. Tung and colleagues identified CYP450 inhibition as the primary pharmacological concern with reishi specifically in patients on active chemotherapy or targeted therapy (2020). No mushroom supplement has been evaluated against every chemotherapy protocol, which is why species, dose, and treatment context all factor into the oncologist's assessment.

What do oncologists say about mushrooms and cancer?

Integrative oncologists apply evidence grades species by species rather than accepting or rejecting mushroom compounds as a category. The 2023 Narayanan systematic review provides the clearest framework: PSK from turkey tail carries Level 1 evidence for gastric and colorectal cancer survival benefit combined with chemotherapy, sufficient to support clinical recommendation in that context. Lentinan carries Level 2 evidence for lung cancer. Reishi carries credible QoL data for fatigue in breast cancer patients on endocrine therapy. For most other widely marketed species, the clinical trial base is insufficient for confident recommendation. Tung and colleagues found that integrative oncologists support patient disclosure and evaluate mushroom supplements as they would any supplement, using evidence grade and interaction profile as their primary criteria (2020).

Do mushroom supplements interfere with chemotherapy?

Some do, through a known biochemical pathway. Reishi contains triterpenoid compounds that inhibit CYP450 liver enzymes (specifically 1A2, 2E1, and 3A4), which are responsible for metabolizing many chemotherapy drugs. When these enzymes are inhibited, drug concentrations can rise above the intended therapeutic range. Turkey tail's polysaccharides may alter the pharmacokinetics of tamoxifen and cyclophosphamide specifically. Shiitake oral supplements and maitake have lower established drug interaction risk, but limited clinical data means the full interaction profile for most species in cancer patients remains incompletely characterized. The absence of documented interactions for a species is not evidence of safety; it reflects limited study.

Should I tell my oncologist I'm taking mushrooms?

Yes, before starting, not after. Reishi's CYP450 inhibition and turkey tail's interaction with tamoxifen are pharmacologically meaningful, and oncologists can only evaluate those interactions against a patient's treatment protocol when they know what is being taken. The Tung 2020 review explicitly identifies the disclosure gap as a clinical risk factor: mushroom supplement use is common among cancer patients, often undisclosed, and the interactions that matter most are the ones the care team doesn't know to look for. The specific information that enables oncologist evaluation includes the product form (extract vs. powder), the dose, the brand, and the timing relative to treatment.

Which mushroom supplements are safest during cancer treatment?

Shiitake-derived lentinan, used as a prescription IV medication in Japan for lung cancer since the 1980s, has the longest clinical safety record in cancer patients. Oral shiitake supplements carry a lower established interaction risk than reishi. Turkey tail PSK has the strongest efficacy data in oncology but requires disclosure due to its interaction with tamoxifen and cyclophosphamide. Reishi has the most significant interaction concern due to CYP450 inhibition and should be evaluated against the patient's specific drug protocol. The 2023 Narayanan systematic review provides the evidence grading across species: PSK (turkey tail) at Level 1, lentinan at Level 2, and reishi with credible QoL data but a lower anti-tumor evidence grade.

Can reishi mushroom interact with cancer drugs?

Yes. Reishi (Ganoderma lucidum) contains triterpenoids that inhibit CYP450 liver enzymes, specifically the 1A2, 2E1, and 3A4 isoforms. These enzymes process many cancer drugs, including chemotherapy agents and targeted therapies. CYP450 inhibition causes those drugs to clear from the body more slowly, which can raise blood concentrations above the intended therapeutic range. Tung and colleagues identified this as the primary pharmacological concern with reishi in cancer patients on active treatment (2020). The interaction is established at the enzyme level; what is less clear is the clinical magnitude at typical supplement doses, which varies by the specific cancer drug involved. This uncertainty is precisely why oncologist evaluation of reishi use is necessary before starting.

Sources & References

1. 1RTHM-01760·Narayanan, Santhosshi et al. (2023). “Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies..” Current oncology reports.Study breakdown →PubMed →↩
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.